Company Overview
IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell product candidates for the treatment of cancer and autoimmune diseases. Its lead product candidates include INB-400, which is in Phase 2 clinical trial to treat newly diagnosed glioblastoma (GBM); INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of GBM; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with hematologic malignancies undergoing hematopoietic stem cell transplantation. The company also develops INB-619, a gamma-delta TCE targeting CD19 for both oncology and autoimmune diseases; INB-300, a nsCAR-enabled DeltEx product candidates targeting difficult liquid tumors and extracranial solid tumors; INB-500, an induced pluripotent stem cell derived gamma-delta T cells that are in preclinical phase for treatment of cancer; and INB-600, a gamma-Delta T cell engager. In addition, it is developing INB-619, a gamma-delta TCE targeting CD19 for potential applications in both oncology and autoimmune diseases. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was incorporated in 2016 and is headquartered in New York, New York.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.12.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -48.42% |
| 6 Months: | -35.59% |
| 3 Months: | -20.83% |
| 1 Month: | +16.45% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)49.76 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 56.0% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | INAB IN8bio, Inc. PHARMA | 1.14 | -0.88 | $11.24M | 0.00% | -66.76% | -111.11% | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income | - | -2.87M | -1.68M | -2.36M | -3.05M | -3.39M | -6.14M | -7.18M | -7.40M | -7.53M | -7.71M | -7.17M | -8.56M | -8.63M | -7.09M | -5.55M | -5.09M | -3.85M | -5.09M | -4.78M |
| Net Income | -1.69M | -2.87M | -1.68M | -2.36M | -3.05M | -3.39M | -6.14M | -7.18M | -7.40M | -7.53M | -7.71M | -7.17M | -8.56M | -8.63M | -7.09M | -5.55M | -5.09M | -3.85M | -5.09M | -4.78M |
| Diluted EPS | - | - | - | - | -1.00 | -0.25 | -0.33 | -0.38 | -0.34 | -0.30 | -0.27 | -0.23 | -0.20 | -5.51 | -4.49 | -2.16 | -1.24 | -0.85 | -0.26 | -0.25 |
| R&D Expense | - | 1.78M | 1.06M | 1.25M | 2.06M | 1.35M | 2.38M | 3.50M | 4.25M | 4.38M | 4.13M | 3.79M | 4.90M | 5.16M | 3.31M | 2.97M | 2.49M | 2.10M | 2.61M | 2.49M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Income | -8.56M | -14.65M | -28.52M | -30.01M | -30.44M | -19.44M |
| Net Income | -8.56M | -14.65M | -28.52M | -30.01M | -30.44M | -19.44M |
| Diluted EPS | - | -1.47 | -1.36 | -1.00 | -17.05 | -4.44 |
| R&D Expense | 5.38M | 7.35M | 14.06M | 16.83M | 16.96M | 10.21M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Total Assets | - | 20.91M | - | 33.04M | 33.71M | 20.94M | 32.28M |
| Current Assets | - | - | - | 22.23M | 24.62M | 12.58M | 27.88M |
| Cash & Equivalents | - | - | - | 18.18M | 21.28M | 11.12M | 27.09M |
| Inventory | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - | - |
| Total Liabilities | - | 2.59M | - | 10.31M | 8.77M | 6.47M | 4.72M |
| Current Liabilities | - | 2.57M | - | 5.82M | 5.39M | 3.08M | 3.16M |
| Long Term Debt | - | - | - | - | - | - | - |
| Total Debt | - | - | - | 5.87M | 4.89M | 5.03M | 2.78M |
| Total Equity | -9.24M | -16.58M | - | 22.73M | 24.94M | 14.48M | 27.56M |
| Shares Outstanding | - | - | - | 818.17K | 1.44M | 2.42M | 9.77M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -7.13M | -13.51M | -24.12M | -23.34M | -24.15M | -12.71M |
| Investing Cash Flow | 0 | -309.00K | -3.71M | -600.00K | -187.00K | 0 |
| Financing Cash Flow | 24.52M | 32.95M | 8.99M | 27.04M | 14.18M | 28.64M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - |
| Net Margin % | - | - | - | - | - | - |
| ROE % | 51.6% | - | -125.5% | -120.3% | -210.2% | -70.5% |
| ROCE % | -46.7% | - | -104.8% | -106.0% | -170.4% | -66.8% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Alyeska Investment Group, L.p. | 9.58% | 944.32K | $1.02M |
| 2 | Franklin Resources, Inc. | 9.28% | 914.53K | $987.69K |
| 3 | 683 Capital Management LLC | 7.35% | 724.64K | $782.61K |
| 4 | Stonepine Capital Management, LLC | 7.05% | 695.29K | $750.91K |
| 5 | Vanguard Capital Management LLC | 0.90% | 88.86K | $95.97K |
| 6 | Bios Capital Management, LP | 0.82% | 80.96K | $87.43K |
| 7 | Geode Capital Management, LLC | 0.74% | 72.55K | $78.35K |
| 8 | Oppenheimer & Co Inc | 0.64% | 63.04K | $68.08K |
| 9 | Citadel Advisors Llc | 0.64% | 63.05K | $68.10K |
| 10 | Vanguard Fiduciary Trust Co | 0.44% | 43.57K | $47.05K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for INAB
INAB Forecast — Price Target — Prediction for 2027 - tradingview.com
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE5jdHRYZmpGWC1PMkhGWkJmNUFqSmJrci0wSmo4ZURweE01clpqU0lteVhMdjNmTnMwZF9ScVlBSVd4SkdDN1RHbmpBUzVNcTJLa1NoeWM3cnRNY0JuODIxcE5IMlV5eW5oNG10N05rNHNyMFUtS3J4V21n?oc=5" target="_blank">INA…
IN8bio (INAB) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMilwFBVV95cUxNV0laQm9kNzlPem9NcVdzRkVDbm9BRkZMS2hfcVZNSEd6OThfa2xZdGJtdUJUWjZ1dThoQWxDVGc3T0lBZW1JX3Jta3c1WFotQnZKZ2JNOGxnT1ByZTZ2MzB0Yk5uRFF2Yk83NUh6RUpnRlZ3Y29ZRFFWMGh0c01UbzNaRTAtLUZEX2ZiaU…
INAB - Finviz
<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTE5FRk5vamUtNXEyeUlqTHdZMmxoMHJ5RUlpSUNwVDBab3c1MlJmb1pnZWhsOXJzQ2pSOWZ5TmJnOXdsQ3c4MlE?oc=5" target="_blank">INAB</a> <font color="#6f6f6f">Finviz</font>…
IN8BIO, Inc. (INAB) investor discloses 9.99% stake and warrant holdings - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiwwFBVV95cUxQbEZlaUZOSFpOci04UmZSdm5mcWRDRVlwY21Qbm5HZ3B3NWxlM0xyX3lzVUVvMXB3SmhpQ21lWVAzVnpxNmFrMzdXUWhKOXpMNi1hdG8yVTdEa2E2eXlkUFF1dy1MZDZnR19VeEhwNDd2NmNTV2x5VHdmLVlvT1gzVkJfY2VXcFdVcU0tQ0…
IN8bio New Employee Receives Option Set to Vest Over Four Years - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiuwFBVV95cUxNU0pHRlA1ZmpvQkdEZlZzeWg4M2tPcEIwcERYeC05R1ZVUWc3YjkyU1RqVG43ZG5yS1RRaUV5bE4ybnoxLVJ6dkc3b1dzdklWV0hqMS1wWFFxRzBKamhNYW4ySzBwNVp2bS1RTTlva2lZQVNueGZxLTRqSjFuT2k4cWoyVWdEOTVEdTdRN2…
IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
<a href="https://news.google.com/rss/articles/CBMi1AFBVV95cUxQZVhydUw3eXNQTE1DWExaRllrb2xiam55U1oxUjIwYmRxMTExWFdfcEhSMWU2OHFwNm9Cai0yX0w5eUZrbjRiM2ZabERTSGViZkdKY3ctNGE0SmJxdmlyNEkzSXUxS2I5cnVna2ZoZVVudWdBODR2RUJrcUVOcEVYT0d4enFWZEhEdE9EYl…
INAB — Frequently Asked Questions
What is the current share price of IN8bio, Inc. (INAB)?
As of 2026-09-19 21:16 PDT, IN8bio, Inc. (INAB) trades at $1.14 on NasdaqCM. Its 52-week range is $0.96 to $2.59.
What is the market capitalisation of INAB?
IN8bio, Inc. (INAB) has a market capitalisation of $11.24M on NasdaqCM.
What is the P/E ratio of INAB?
INAB trades at a trailing price-to-earnings (P/E) ratio of -0.88. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 0.58.
What is the return on equity (ROE) of INAB?
INAB has a return on equity (ROE) of -111.11%. Its return on capital employed (ROCE) is -66.76%.
Is INAB a good stock to buy?
This page provides a data-driven analysis of IN8bio, Inc. (INAB), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.